Blood markers may predict immunotherapy success in advanced cancers
NCT ID NCT03595813
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This study aimed to find blood-based markers that could predict how well cancer immunotherapy works. Researchers collected blood samples from 135 adults with advanced lung cancer, lymphoma, or urologic cancers before and during treatment. They measured immune-suppressing cells and molecules to see if changes in these markers could forecast treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Paoli-Calmettes
Marseille, Bouches-du-Rhône, France
Conditions
Explore the condition pages connected to this study.